SCHEMBL394152

SCHEMBL394152

Cc1[nH]c(C=C2C(=O)Nc3c(Nc4cccc(NC(=O)c5ccc(CN6CCN(C)CC6)cc5)c4)cccc32)c(C)c1C(=O)NCCN1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 7/20 0.54
KDR P35968 7/20 0.54
FGFR1 P11362 5/20 0.54
TLK2 Q86UE8 1/20 0.54
RET P07949 2/20 0.52
FLT3 P36888 3/20 0.51
AURKB Q96GD4 2/20 0.51
MET P08581 1/20 0.51
NTRK2 Q16620 1/20 0.50
LCK P06239 2/20 0.47
KIT P10721 2/20 0.47
KCNH2 Q12809 2/20 0.47
NTRK1 P04629 2/20 0.47
AURKA O14965 1/20 0.47
BTK Q06187 1/20 0.46
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
ABL1 P00519 2/20 0.41
CHEK1 O14757 1/20 0.41
FYN P06241 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091910 1.00 PDGFRB (0.54) PDGFRBKDRFGFR1TLK2RET
SCHEMBL10091909 0.93 NTRK2 (0.56) PDGFRBKDRFGFR1TLK2RET
SCHEMBL397241 0.93 NTRK2 (0.56) PDGFRBKDRFGFR1TLK2RET
SCHEMBL4128697 0.92 RET (0.55) PDGFRBKDRFGFR1TLK2RET
SCHEMBL4128689 0.92 RET (0.55) PDGFRBKDRFGFR1TLK2RET
SCHEMBL10091908 0.91 FLT3 (0.54) PDGFRBKDRFGFR1TLK2RET
SCHEMBL397630 0.91 FLT3 (0.54) PDGFRBKDRFGFR1TLK2RET
SCHEMBL394470 0.91 KDR (0.57) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL10091907 0.91 KDR (0.57) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL10091885 0.87 FLT3 (0.63) PDGFRBKDRFGFR1TLK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US disclosed